Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical stage RXR agonist for treatment of normal aging-related neurodegeneration, at the FASEB Science Research Conference on Cellular and Molecular Mechanisms of Brai 18-09-2024, 22:07

Invite: TRREB’s 2023 Market Outlook and 2022 Year in Review 18-02-2023, 03:41

HYCU Delivers Industry-First Backup for Microsoft 365 and Cloud Services With 100% Data Control and Storage Efficiency 21-05-2025, 02:01